抗SARS-CoV-2超免疫球蛋白和静脉注射免疫球蛋白对当前流行的SARS-CoV-2变体的中和活性。 - Suppr

Suppr

超能文献

Neutralizing activity of anti-SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants.

作者信息

Bellusci Lorenza, Golding Hana, Khurana Surender

出版信息

J Clin Invest. 2024 Jul 25;134(20):e182919. doi: 10.1172/JCI182919.

DOI:10.1172/JCI182919

PMID:39403934

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11473157/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/658c/11473157/76352c89d24f/jci-134-182919-g208.jpg

相似文献

Neutralizing activity of anti-SARS-CoV-2 hyperimmune immunoglobulins and intravenous immunoglobulins against currently circulating SARS-CoV-2 variants.抗SARS-CoV-2超免疫球蛋白和静脉注射免疫球蛋白对当前流行的SARS-CoV-2变体的中和活性。

J Clin Invest. 2024 Jul 25;134(20):e182919. doi: 10.1172/JCI182919.

Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants.评估静脉注射免疫球蛋白对未来新冠病毒变体的中和活性可能降低的情况。

Transfusion. 2021 Aug;61(8):2514-2515. doi: 10.1111/trf.16553.

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic.静脉注射用免疫球蛋白无法中和 2020 年大流行前采集的血浆中分离的 SARS-CoV-2。

J Infect Dis. 2020 Nov 13;222(12):1960-1964. doi: 10.1093/infdis/jiaa593.

Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.根据 BNT162b2 疫苗接种和感染史，抗 SARS-CoV-2 免疫球蛋白同种型和对病毒变异体的中和活性。

Front Immunol. 2021 Dec 17;12:793191. doi: 10.3389/fimmu.2021.793191. eCollection 2021.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。

Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.

Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.从汇集的 COVID-19 恢复期血浆中生产抗 SARS-CoV-2 静脉用免疫球蛋白。

Immunotherapy. 2021 Apr;13(5):397-407. doi: 10.2217/imt-2020-0263. Epub 2021 Feb 9.

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.COVID-19 恢复期个体中中和抗体的时间成熟提高了对流行的 SARS-CoV-2 变体的效力和广度。

Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2.

Neutralizing SARS-CoV-2.中和 SARS-CoV-2

Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.目前的静脉注射免疫球蛋白对 SARS-CoV-2 具有交叉中和活性。

Immunotherapy. 2020 Dec;12(17):1247-1255. doi: 10.2217/imt-2020-0220. Epub 2020 Sep 8.

Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.从 COVID-19 恢复期血浆中开发和表征抗 SARS-CoV-2 静脉用免疫球蛋白。

Immunotherapy. 2022 Oct;14(14):1133-1147. doi: 10.2217/imt-2022-0015. Epub 2022 Jul 27.

引用本文的文献

Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants.标准和超免疫静脉注射免疫球蛋白对近期流行的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和活性

Vaccines (Basel). 2025 Jul 17;13(7):760. doi: 10.3390/vaccines13070760.

本文引用的文献

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.新冠病毒奥密克戎变异株加强免疫可诱导人体产生新的 B 细胞反应。

Nature. 2023 May;617(7961):592-598. doi: 10.1038/s41586-023-06025-4. Epub 2023 Apr 3.

Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms.长期大剂量免疫球蛋白成功治疗有肺部、神经和心脏症状的长新冠患者。

Front Immunol. 2023 Feb 2;13:1033651. doi: 10.3389/fimmu.2022.1033651. eCollection 2022.

Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Intravenous Human Immunoglobulins Neutralizes Omicron Subvariants BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/BA.5 for Treatment of Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒 2 超免疫静脉注射人免疫球蛋白中和奥密克戎亚变种 BA.1、BA.2、BA.2.12.1、BA.3 和 BA.4/BA.5 用于治疗 2019 年冠状病毒病。

Clin Infect Dis. 2023 Feb 8;76(3):e503-e506. doi: 10.1093/cid/ciac642.

Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.静脉注射用免疫球蛋白由新冠康复期及新冠疫苗接种者捐献的血浆制成，对 SARS-CoV-2 具有高效中和作用。

J Infect Dis. 2021 Nov 22;224(10):1707-1711. doi: 10.1093/infdis/jiab482.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.肾细胞癌肾切除术后辅助帕博利珠单抗。

N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验